QualityStocksNewsBreaks Archives - Page 852 of 1517

WednesdayFeb 24, 2021 11:39 am

QualityStocksNewsBreaks – Kaival Brands Innovations Group Inc. (KAVL) Announces Bidi Vapor’s Advancement to Final FDA PMTA Phase for all 11 Bidi(R) Stick Flavors

Kaival Brands (OTCQB: KAVL), a company focused on generating stockholder value by incubating innovative products into mature and dominant brands, is the exclusive global distributor of all products manufactured by Bidi Vapor LLC. Bidi Vapor's primary offering, the Bidi (R) Stick, is the fastest-growing closed system vaping product in the U.S. and the only vape product on the market with an ecologically friendly, mass-recycling program. Bidi Vapor has received a Premarket Tobacco Product Application (“PMTA”) filing letter from the U.S. Food and Drug Administration (“FDA”) for its family of disposable e-cigarettes called Bidi (R) Stick, which comes in 11 flavor…

WednesdayFeb 24, 2021 11:02 am

QualityStocksNewsBreaks – Sigma Labs Inc. (NASDAQ: SGLB) to Sponsor, Present at AM Industry Aerospace and Energy Summit

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial metal 3D printing industry, today announced that it is a sponsor of the AM Industry Summit, to be held virtually on March 3-4, 2021. This year's event, powered by the American Society of Mechanical Engineers ("ASME"), brings together the aerospace and energy industries with leading solution providers to share knowledge, connect with experts, and find ideas to accelerate their use of additive manufacturing.  Sigma Labs CTO Darren Beckett will present an information session 3:45 p.m. Eastern Time on March 3, titled "Boosting Additive Manufacturing Quality, Economics…

WednesdayFeb 24, 2021 10:45 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enters Agreement for Upcoming Berubicin Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (8SV1.F) (“WPD”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, have entered into an agreement for WPD to obtain Investigational Medicinal Product (“IMP”) classification for Berubicin for its use in upcoming clinical trials. According to the update, WPD will purchase half of the batch previously manufactured for CNS by BSP Pharmaceuticals for the WPD-201 and WPD-201P studies, planned to begin in the first half of 2021. Berubicin is a novel anthracycline candidate for the treatment of a number…

WednesdayFeb 24, 2021 10:41 am

QualityStocksNewsBreaks – Ideanomics (NASDAQ: IDEX) Announces Presence at Three Upcoming Conferences

Ideanomics (NASDAQ: IDEX), a global company focused on the convergence of financial services and industries experiencing technological disruption, along with two portfolio companies — WAVE (“WAVE”) and Selectrac — will be presenting at three virtual conferences, all scheduled in March. WAVE’s Michael Masquelier will present at the Global Transmission Conference, schedule for March 4, 2021. Masquelier’s 40-minute presentation will begin at 1:15 p.m. ET. Solectrac founder and CEO Steve Heckeroth will present at FORCE for Knowledge: Food Tech 101 on March 10, 2021. His one-hour presentation will begin at 11 a.m. ET. Ideanomics CEO Alf Poor will participate in an EV panel at…

WednesdayFeb 24, 2021 10:15 am

QualityStocksNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) Announces Receipt of Regulatory Approval Powdery Mildew Bio-Fungicide in Canada

MustGrow Biologics (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, has received regulatory approval from Canada’s Pest Management Regulatory Agency (“PMRA”) for use of a powdery mildew bio-fungicide product; the approval covers use of the powdery mildew bio-fungicide suppression treatment on cannabis and hemp products. MustGrow announced more than a year ago that it had completed a definitive licensing agreement to obtain the exclusive treatment from a leading multinational biological and microbial company. The bio-fungicide product, which is not mustard derived, like MustGrow’s other products, is designed to…

WednesdayFeb 24, 2021 10:11 am

QualityStocksNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces First Order for Rapid COVID-19 Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has placed an initial order for rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system. The test systems, known as COVID-ID Labs, were ordered from XPhyto’s exclusive diagnostic development partner, 3a-diagnostics GmbH ("3a"). The first order consists of 9,600 individual tests; the tests are packaged in 200 kits of 48 tests each. The tests, which should arrive by mid-March 2021, will be used as samples for review and evaluation and will be primarily given to prospective distribution partners and licensees…

WednesdayFeb 24, 2021 10:01 am

QualityStocksNewsBreaks – Friendable Inc.’s (FDBL) Fan Pass Live Sees 100% Growth in Live Stream Events, Artist Performances

Friendable (OTC: FDBL), a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications, has released an update on its Fan Pass platform. The platform is seeing validating signs in several key categories of growth metrics, including 100% growth in live-stream events and artist performances. FDBL noted that as the month ends, it anticipates that activity will continue to increase, resulting in numbers higher than seen in January 2021. “Metrics mean everything, no matter whether they’ve increased or decreased, and they continue to guide our team on the journey toward success on…

WednesdayFeb 24, 2021 9:43 am

QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Appoints New Chairman of the Board

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced the appointment of James Sapirstein, president and CEO, as chairman of the company’s board of directors, effective immediately. Sapirstein succeeds Edward J. Borkowski, who joined the AzurRx board in May 2015 and has served as chairman since April 2016. Borkowski will remain as lead independent director of the board of directors. “Having served on AzurRx’s board since 2015, I am committed to ensuring a prosperous future for the company,” said Borkowski. “Under James’ leadership, AzurRx has strategically expanded…

WednesdayFeb 24, 2021 9:32 am

QualityStocksNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes $17.6M Private Placement; Reaches Key Milestones in Developing AI-Driven Model of Ovarian Cancer

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery closed on its previously announced private placement of common stock and warrants. Priced at-the-market under Nasdaq rules, the 9,043,766 shares of common stocks and warrants were issued and sold by the company in order to purchase no more than 4,521,883 shares of common stock in the private placement. The common stock and associated warrants were issued for $1.95 each, with the warrants having an exercise price of $2 per share. The shares are exercisable immediately; however, they do have a five and…

TuesdayFeb 23, 2021 3:32 pm

QualityStocksNewsBreaks – United Medical Equipment Business Solutions Network Inc.’s App Addresses Treatment Barriers

United Medical Equipment (“UME,” “UMEBSNI”) is focused on providing reliable resources and solutions to help health-care systems work smarter, providers work more proficiently, and patients live healthier lives. Essential to any treatment plan are medication management and collaboration between patient and physician. Two large barriers in medication adherence include poor provider-patient communication and inadequate knowledge about a drug (https://ibn.fm/qzXy6). United Medical has developed a medication management solution to address these barriers: a free app available for download on the Apple App Store and Google Play. A recent article discussing the solution reads, “The free seven-day trial version of the Medication…

Site Search

Company Search

Category: QualityStocksNewsBreaks